Preclinical combination therapy of clofarabine plus radiation

Nucleosides, Nucleotides and Nucleic Acids

Volumn 31, Issue 9, 2012, Pages 692-705

  Stackhouse, Murray A ^a   Gilbert, Karen S ^a   Scoggins, Jeffery W ^a   Waud, William R ^a  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

Clofarabine; combination therapy; gemcitabine; human tumor xenograft; radiation

Indexed keywords

CLOFARABINE; GEMCITABINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; CELL STRAIN; COLON TUMOR; GLIOBLASTOMA; HEAD AND NECK TUMOR; HUMAN; HUMAN CELL; LUNG TUMOR; MULTIMODALITY CANCER THERAPY; PANCREAS TUMOR; PROSTATE TUMOR; RADIATION DOSE; TUMOR XENOGRAFT;

ADENINE NUCLEOTIDES; ANIMALS; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DRUG EVALUATION, PRECLINICAL; HUMANS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867031814     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257770.2012.723770     Document Type: Article

References (8)

1. Montgomery, J.A.; Shortnacy-Fowler, A.T.; Clayton, S.D.; Riordan, J.M.; Secrist, J.A. III. Synthesis and biologic activity of 2′-fluoro-2-halo derivatives of 9-beta-D-arabinofuranosyladenine. J. Med. Chem. 1992, 35, 397-401.
2. Waud, W.R.; Schmid, S.M.; Montgomery, J.A.; Secrist, J.A. III. Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-β-D- arabinofuranosyl)adenine (C1-F-ara-A). Nucleos. Nucleot. Nucl. Acids 2000, 19, 447-460.
3. Waud, W.R.; Gilbert, K.S.; Secrist, J.A. III; Shepherd, R.V.; Tiwari, K.N. Preclinical antitumor activity of 4′-thio-β-D- arabinofuranosylcytosine (4′-thio-ara-C, OSI-7836) in human leukemia and lymphoma xenograft models. Proc. Amer. Assoc. Cancer Res. 2004, 45, 714.
4. Cariveau, M.J.; Stackhouse, M.; Cui, X.L.; Tiwari, K.; Waud, W.; Secrist, J.A. III; Xu, B. Clofarabine acts as radiosensitizer in vitro and in vivo by interfering with DNA damage response. Int. J. Radiat. Oncol. Biol. Phys. 2008, 70, 213-220.
5. Stackhouse, M.; Gilbert, K.; Scoggins, J.; Waud, W.R. Evaluation of the radiosensitizing potential of clofarabine in six xenograft models. Proc. Amer. Assoc. Cancer Res. 2008, 49, 97.
6. Mason, K.A.; Milas, L.; Hunter, N.R.; Elshaikh, M.; Buchmiller, L.; Kishi, K.; Hittelman, K.; Ang, K.K. Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int. J. Radiat. Oncol. Biol. Phys. 1999, 44, 1125-1135.
7. Fields, M.T.; Eisbruch, A.; Normolle, D.; Orfali, A.; Davis, M.A.; Pu, A.T.; Lawrence, T.S. Radiosensitization produced in vivo by once- vs. twice-weekly 2′2′-difluoro-2′-deoxycytidine (gemcitabine). Int. J. Radiat. Oncol. Biol. Phys. 2000, 47, 785-791.
8. Kantarjian, H.M.; Gandhi, V.; Kozuch, P.; Faderl, S.; Giles, F.; Cortes, J.; O'Brien, S.; Ibrahim, N.; Khuri, F.; Du, M.; Rios, M.B.; Jeha, S.; McLaughlin, P.; Plunkett, W.; Keating, M. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J. Clin. Oncol. 2003, 21, 1167-1173.